TGAT
SIBM
Market cap16mUSD
, Last price
EUR
Name
Sirona Biochem Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sirona Biochem Corp. operates as a biotechnology company dedicated to uncovering and commercializing active ingredients for both cosmetic and pharmaceutical uses, with a commercial presence in Canada and France. Key initiatives include the development of a cosmetic skin brightener and a pharmaceutical solution for diabetes. Beyond these, the company is engaged in several other projects, such as building a library of anti-aging and cell-protective compounds, creating a novel anti-wrinkle agent, and pursuing an antiviral research program. A notable collaboration exists with the International Centre for Genetic Engineering and Biotechnology (ICGEB) for the joint development of an antiviral compound library. Established in 2006, the business, originally named High Rider Capital Inc., rebranded as Sirona Biochem Corp. in May 2009 and maintains its headquarters in Vancouver, Canada.
Key people
Howard Verrico
Chairman of the Board, Interim Chief Executive Officer, Founder, Secretary · since 2014
Geraldine Deliencourt-Godefroy
Chief Scientific Officer, Director · since 2012
Attila Hajdu
Chief Business Development Officer · since 2014
Christopher D. Hopton
Chief Financial Officer, Director · since 2011
Alex Marazzi
Independent Director · since 2006
Headquarters & legal address
889 West Pender Street
Suite 605
Vancouver, BC V6C 3B2
CA
Suite 605
Vancouver, BC V6C 3B2
CA
Previous name
High Rider Capital Inc.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||